Charts

Gainers Inspire Veterinary (NASDAQ:IVP) stock rose 10.8% to $0.27 during Tuesday's after-market session. The company's market cap ...

CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) shareholders might be concerned after seeing the share price drop 22% in the...

CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, at the Lotte New York Palace in New York City. Members of the CASI management team, including Chief Financial Officer Daniel Lang, MD, and C

InvestorPlace - Stock Market News, Stock Advice & Trading Tips CASI stock results show that CASI Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. The post CASI Stock Earnings: CASI Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024 appeared first on InvestorPlace. More From InvestorPlace Legendary Investor Predicts: “Forget AI... THIS Technology Is the Future”

CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company specializing in the development and commercialization of innovative therapeutics and pharmaceutical products, today reported business updates and financial results for the three months ended June 30, 2024.

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Healthcare innovations are big business. That said, biotech stocks under $10 may offer a higher ceiling thanks to their low price. The post 3 Promising Biotech Stocks You Can Pick Up for Less Than $10 appeared first on InvestorPlace. More From InvestorPlace Legendary Investor Predicts: “Forget AI... THIS Technology Is the Future”

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please visit below link:

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products today announces appointment of Daniel Lang, MD as Chief Financial Officer and Senior Vice President, effective July 8th, 2024.

Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to support its portfolio of drugs.

CASI Pharmaceuticals (CASI) gets a proposal letter from its chairman for acquiring its business operations in China. Its shares rise on the news.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are worth checking out on Thursday as we dig into all of the biggest news moving shares this morning! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future”

CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, announced today that the Company is planning to submit an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA") for CID-103 for the treatment of antibody-mediated rejection ("AMR") in kidney transplant recipients by the end of 2024. CID-103 is a fully hu

CASI Pharmaceuticals, Inc. (Nasdaq: CASI) ("CASI" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, announced today that it has entered into securities purchase agreements with certain investors for a private investment in public equity financing (the "PIPE Transaction") that is expected to result in aggregate gross proceeds of approximately $15.0 million, before deducting placement agent fe

Gainers DermTech (NASDAQ:DMTK) stock rose 56.6% to $0.18 during Friday's pre-market session. The market value of their outstanding ...

Gainers Molecular Partners (NASDAQ:MOLN) stock rose 39.1% to $11.07 during Thursday's regular session. The market value of their ...

Gainers SINTX Techs (NASDAQ:SINT) stock moved upwards by 143.1% to $0.13 during Wednesday's pre-market session. The company's market ...

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products announced today the following: On April 12, 2024 CASI submitted the IND application to the FDA for CID-103 to support a phase 1/2 study of CID-103 in adults with chronic Immune Thrombocytopenia (ITP). On May 13, 2024 CASI received a letter from FDA indicating that study may proceed.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. The post CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. Legendary Investor Predicts: “Forget A.I. THIS Technology Is the Future”

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the three months ended March 31, 2024.

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern Time to discuss this announcement and answer questions.

With the business potentially at an important milestone, we thought we'd take a closer look at CASI Pharmaceuticals...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips CASI stock results show that CASI Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. The post CASI Stock Earnings: CASI Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 appeared first on InvestorPlace. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million. Do this now.

CASI Pharmaceuticals (NASDAQ:CASI) reported its Q4 earnings results on Thursday, March 28, 2024 at 07:00 AM. Here's what investors need ...

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the year ended December 31, 2023, and provided an update on key highlights for 2023.

Gainers Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 137.8% to $3.02 during Friday's regular session. The market value of ...

Gainers NKGen Biotech (NASDAQ:NKGN) stock rose 18.0% to $2.16 during Thursday's pre-market session. The company's market cap stands at ...

CASI Pharmaceuticals Inc(NASDAQ:CASI) andBioInvent International ABannounced preliminary efficacy data for BI-1206 in ...

Gainers Sunshine Biopharma (NASDAQ:SBFM) stock moved upwards by 55.9% to $0.07 during Tuesday's pre-market session. The market value of ...

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced preliminary encouraging efficacy data for BI-1206 in combination with rituximab in patients

LianBio, a Princeton-Shanghai biotech, has decided to call it quits. LianBio plans to stop all of its operations by the end of 2024, and it will distribute a $4.80 dividend/share ($528 million) to its shareholders.

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, proudly announced the administration of the first dose of FOLOTYN® (Pralatrexate Injection) to a patient in China. This remarks a pivotal step in CASI's commitment to addressing critical medical needs in peripheral T-cell lymphoma in China market.

Gainers Inspire Veterinary (NASDAQ:IVP) stock moved upwards by 37.5% to $0.26 during Thursday's after-market session. The market value ...

Despite an already strong run, CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) shares have been powering on, with a gain of...

CASI Pharmaceuticals, Inc. ( NASDAQ:CASI ) is possibly approaching a major achievement in its business, so we would...

HC Wainwright & Co. has decided to maintain its Buy rating of CASI Pharmaceuticals (NASDAQ:CASI) and raise its price target from ...

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported business and financial results for the third quarter ended September 30, 2023.

CASI Pharmaceuticals Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, is thrilled to announce a major milestone in its partnership with Juventas Cell Therapy Ltd. (Juventas). The China National Medical Products Administration (NMPA) has granted market approval for Juventas' investigational cell therapy, Inaticabtagene Autoleucel (CNCT 19), for the treatment of relapsed and refractory B-cell acute lymph

Gainers Sensei Biotherapeutics (NASDAQ:SNSE) shares moved upwards by 13.0% to $0.78 during Friday's after-market session. The market ...

Gainers Tempest Therapeutics, Inc. (NASDAQ: TPST) shares rose 279.8% to $0.9115 in pre-market trading, after the company announced ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Pre-market stock movers are a hot topic on Wednesday morning and we're covering all of the latest news investors need to know about! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday appeared first on InvestorPlace. More From InvestorPlace Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. ChatGPT IPO Could Shock the World, Make This Move Before the Announcement The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors

Gainers Gritstone Bio (NASDAQ:GRTS) stock rose 37.0% to $1.63 during Wednesday's after-market session. Today's trading volume for this ...

Mundipharma is considering selling its China operations in a deal that could be worth $1 billion. Additionally, Oramed Pharma plans to form a $60 million JV with Hefei Tianhui Biotech to commercialize Oramed's oral drug delivery products globally.

Novartis signed a $1 billion agreement to acquire DTx Pharma, a preclinical San-Diego company developing siRNA therapies for neuroscience indications. Meanwhile, Zhuhai Biotheus formed a far-reaching research/license collaboration with BioNTech SE.

Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that CASI Pharmaceuticals (NASDAQ: CASI) has acquired the global rights to the company’s clinical asset, CB-5339, and Eikon Therapeutics has acquired rights to the company’s pre-clinical assets. CASI Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products. Eikon Therapeutics is a clinical-stage company working to advance breakthrough therapeutics through the purposeful integration of engineering and science.

CASI Pharmaceuticals (NASDAQ:CASI) reported its Q1 earnings results on Wednesday, May 17, 2023 at 07:35 AM. Here's what investors need ...

CASI Pharmaceuticals (NASDAQ:CASI) brought in sales totaling $15.26 million during Q4 according to data provided by Benzinga Pro. ...

Gainers GlucoTrack (NASDAQ:GCTK) shares rose 194.1% to $3.5 during Monday's regular session. Trading volume for this security as of ...

According to data from Benzinga Pro, during Q3, CASI Pharmaceuticals's (NASDAQ:CASI) reported sales totaled $10.21 million. Despite a ...

Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday. Kiromic BioPharma, ...

Chia Tai-Tianqing Pharma, a subsidiary of Sino Biopharma, in-licensed Greater China rights to a therapy for non-alcoholic steatohepatitis from Inventiva in a $307 million deal. Meanwhile, CASI Pharma sold its 12% stake in its partner for $34 million.

Beijing BoomRay Pharma, a joint venture between WuXi AppTec and Peking University, completed a $43 million Series A funding to develop novel radionuclide drugs that integrate diagnosis and treatment.

The Dow Jones closed higher by around 193 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When ...

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders ...

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at a noteworthy recent insider buy.

Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter ...

Gainers Artelo Biosciences (NASDAQ:ARTL) stock increased by 46.9% to $6.4 during Tuesday's regular session. Trading ...

CASI Pharmaceuticals (NASDAQ:CASI) reported its Q2 earnings results on Friday, August 12, 2022 at 07:00 AM. Here's what ...

Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per ...

Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported ...

Gainers Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing ...

CASI Pharmaceuticals (NASDAQ:CASI) is set to give its latest quarterly earnings report on Friday, 2022-08-12. Here's what ...

Gainers Missfresh Limited (NASDAQ: MF) shares rose 112.9% to $0.2450 in pre-market trading after dropping 7% on ...

New investments in China life science may have declined over the last year, but large investment companies continue to raise large sums to invest. Sequoia China has raised about $9 billion to make investments in China’s healthcare and tech companies.